Literature DB >> 25483696

Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines.

Yang Zang1, Dongchuan Du, Peng Ge, Yongqing Xu, Xintao Liu, Yan Zhang, Weiheng Su, Irina Kiseleva, Larisa Rudenko, Fei Xu, Wei Kong, Chunlai Jiang.   

Abstract

Traditionally, infectivity of a trivalent live attenuated influenza vaccines (LAIVs) is titrated by determining the 50% egg infectious dose assay (EID50) or plaque forming units (PFU), which requires specific monoclonal antibodies to neutralize 2 strains while estimating the titer of the non-neutralized strain. Compared to this time-consuming, laborious, subjective and variable process, reverse transcription-quantitative real-time PCR (RT-qPCR) technology has advantages of rapidity, sensitivity, reproducibility and reduced contamination, thus has been applied widely for detecting pathogens and measuring viral titers. In this study, the critical harvest time was determined to be 18 h post-infection (hpi) for type A influenza and 12 hpi for type B influenza, but no significant difference between titers at 12 hpi and 18 hpi for the type B strain was observed. In conclusion, trivalent LAIVs can be titrated simultaneously within 24 h by this one-step RT-qPCR assay, which yielded titers comparable to those obtained by the traditional EID50 assay. Therefore, the RT-qPCR assay may be used as a highly specific, sensitive, precise and rapid alternative to the EID50 assay for titering LAIVs.

Keywords:  50% egg infectious dose assay; CV%, coefficient of variation; Ct, Cycle threshold; E, efficiency; EID50, 50% egg infectious dose assay; HA, hemagglutinin; LAIVs, live attenuated influenza vaccines; NA, neuraminidase; R2, Correlation coefficient values; RT-qPCR, reverse transcription-quantitative real-time PCR; SD, standard deviation; hpi, hour post-infection; infectivity; live attenuated influenza vaccine; quantitative real-time PCR; titration

Mesh:

Substances:

Year:  2014        PMID: 25483696      PMCID: PMC4514063          DOI: 10.4161/hv.34453

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

Review 1.  Real-time PCR in virology.

Authors:  Ian M Mackay; Katherine E Arden; Andreas Nitsche
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

2.  Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR.

Authors:  Johanna A C Schalk; Christa van den Elzen; Hans Ovelgönne; Chantal Baas; Peter M J M Jongen
Journal:  J Virol Methods       Date:  2004-05       Impact factor: 2.014

3.  Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).

Authors:  Todd Ranheim; Pamela K Mathis; Daniel B Joelsson; Mary Ellen Smith; Kathryn M Campbell; Gwendolyn Lucas; Scott Barmat; Erin Melissen; Robert Benz; John A Lewis; Jie Chen; Timothy Schofield; Robert D Sitrin; John P Hennessey
Journal:  J Virol Methods       Date:  2005-10-07       Impact factor: 2.014

4.  Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

Authors:  Suzanne E Ohmit; John C Victor; Judy R Rotthoff; Esther R Teich; Rachel K Truscon; Laura L Baum; Bhavya Rangarajan; Duane W Newton; Matthew L Boulton; Arnold S Monto
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

5.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

Authors:  R B Belshe; P M Mendelman; J Treanor; J King; W C Gruber; P Piedra; D I Bernstein; F G Hayden; K Kotloff; K Zangwill; D Iacuzio; M Wolff
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

6.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

7.  Quantitative PCR: a quality control assay for estimation of viable virus content in live attenuated goat pox vaccine.

Authors:  D J Kallesh; M Hosamani; V Balamurugan; V Bhanuprakash; V Yadav; R K Singh
Journal:  Indian J Exp Biol       Date:  2009-11       Impact factor: 0.818

8.  Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays.

Authors:  Kamol Suwannakarn; Sunchai Payungporn; Thaweesak Chieochansin; Rujipat Samransamruajkit; Alongkorn Amonsin; Thaweesak Songserm; Arunee Chaisingh; Pornchai Chamnanpood; Salin Chutinimitkul; Apiradee Theamboonlers; Yong Poovorawan
Journal:  J Virol Methods       Date:  2008-07-15       Impact factor: 2.014

9.  Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.

Authors:  Ali Azizi; Mei Tang; Lucy Gisonni-Lex; Laurent Mallet
Journal:  BMC Microbiol       Date:  2013-12-06       Impact factor: 3.605

Review 10.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Authors:  Christopher S Ambrose; Catherine Luke; Kathleen Coelingh
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more
  2 in total

1.  Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Irina Isakova-Sivak; Svetlana Donina; Andrey Rekstin; Maria Pisareva; Ekaterina Bazhenova; Tatiana Kotomina; Anastasia Katelnikova; Arman Muzhikyan; Valery Makarov; Erin Grace Sparrow; Guido Torelli
Journal:  Vaccines (Basel)       Date:  2018-11-01

2.  Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Andrey Rekstin; Svetlana Donina; Maria Pisareva; Elena Grigorieva; Kirill Kryshen; Arman Muzhikyan; Marina Makarova; Erin Grace Sparrow; Guido Torelli; Marie-Paule Kieny
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.